Thomas Cahill, MD, PhD
Dr. Cahill is the co-founder and Managing Director of Newpath Partners. Prior to Newpath, he worked at the Raptor Group, where he helped further establish and lead the life science/healthcare and technology investment portfolio. His focus is on uniquely aligning interests between academics, investors, and management. Dr. Cahill received both his MD and PhD from Duke University. His PhD work, with Professor Robert Lefkowitz (Nobel Laureate), focused on the biophysical and structural properties of cellular receptors and their signaling to inform novel drug development and discovery. Dr. Cahill’s research experience spans the basic sciences and pharmaceutical landscape. He recently started a company, Molindra Therapeutics, focused on discovering drugs for a new class of receptor target.
Dr. Cahill’s work has led to numerous peer-reviewed publications and awards. He obtained an MS in chemistry from Stanford University, focused on reaction dynamics and drug delivery in the laboratory of Professor Richard Zare. As an undergraduate, Dr. Cahill performed research at Cornell University with Professor Roald Hoffmann (Nobel Laureate), focused on theoretical and computational chemistry.